Medtronic investigation
This article was originally published in The Gray Sheet
Executive Summary
Department of Justice sends a letter to Medtronic Nov. 16 requesting any information that the firm also is providing to the Securities and Exchange Commission related to SEC's investigation into possible violations of the U.S. Foreign Corrupt Practices Act, the firm notes in its Dec. 4 quarterly SEC filing. The firm says it is cooperating with DoJ and SEC. In September, SEC notified Stryker, Zimmer, Biomet, Smith & Nephew and Medtronic that it is investigating potential corrupt practices related to the companies' sales of devices in an unspecified number of countries including Greece, Poland and Germany (1"The Gray Sheet" Oct. 22, 2007, p. 10)
You may also be interested in...
Foreign Corrupt Practices Act: Device Industry Under Scrutiny
Federal prosecutors have begun targeting medical device companies in Foreign Corrupt Practices Act investigations
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.